McDorman, Kevin S, Bennet, Bindu M, Colman, Karyn, Fikes, James D, Keirstead, Natalie D, Lanning, Lynda, Munch, Barbara, Romeike, Annette, Schafer, Kenneth A, Schorsch, Frederic, Thibodeau, Michael S, Thomas, Heath C, Troth, Sean, Vahle, John L and Geoly, Frank J (2024) Scientific and Regulatory Policy Committee Points to Consider: Review of the United States Food and Drug Administration (FDA) Guidance on Pathology Peer Review in Nonclinical Toxicology Studies. Toxicologic pathology. p. 1926233241248654. ISSN 1533-1601

Abstract

In December 2021, the United States Food and Drug Administration (FDA) issued the final guidance for industry titled Pathology Peer Review in Nonclinical Toxicology Studies: Questions and Answers. The stated purpose of the FDA guidance is to provide information to sponsors, applicants, and nonclinical laboratory personnel regarding the management and conduct of histopathology peer review as part of nonclinical toxicology studies conducted in compliance with good laboratory practice (GLP) regulations. On behalf of and in collaboration with global societies of toxicologic pathology and the Society of Quality Assurance, the Scientific and Regulatory Policy Committee (SRPC) of the Society of Toxicologic Pathology (STP) initiated a review of this FDA guidance. The STP has previously published multiple papers related to the scientific conduct of a pathology peer review of nonclinical toxicology studies and appropriate documentation practices. The objectives of this review are to provide an in-depth analysis and summary interpretation of the FDA recommendations and share considerations for the conduct of pathology peer review in nonclinical toxicology studies that claim compliance to GLP regulations. In general, this working group is in agreement with the recommendations from the FDA guidance that has added clear expectations for pathology peer review preparation, conduct, and documentation.

Item Type:	Article
Date Deposited:	21 Jun 2024 00:46
Last Modified:	21 Jun 2024 00:46
URI:	https://oak.novartis.com/id/eprint/48775